|
|
Ethinyl
Estradiol and Levonorgestrel |
| |
|
Pronunciation |
|
(ETH
in il es tra DYE ole & LEE
voe nor jes trel) |
|
|
U.S. Brand
Names |
|
Alesse™; Levlen®;
Levlite®; Levora®; Nordette®; PREVEN™;
Tri-Levlen®; Triphasil® |
|
|
Generic
Available |
|
Yes |
|
|
Synonyms |
|
Levonorgestrel and Ethinyl Estradiol |
|
|
Pharmacological Index |
|
Contraceptive |
|
|
Use |
|
Prevention of pregnancy; treatment of hypermenorrhea, endometriosis, female
hypogonadism |
|
|
Pregnancy Risk
Factor |
|
X |
|
|
Contraindications |
|
Thrombophlebitis, undiagnosed vaginal bleeding, hypersensitivity to ethinyl
estradiol or any component, known or suspected pregnancy, carcinoma of the
breast, estrogen-dependent tumor |
|
|
Warnings/Precautions |
|
Use of any progestin during the first 4 months of pregnancy is not
recommended; use with caution in patients with asthma, seizure disorders,
migraine, cardiac, renal or hepatic impairment, cerebrovascular disorders or
history of breast cancer, past and present thromboembolic disease, smokers
>35 years of age. Products containing 50 mcg of estrogen should be used only
when medically indicated (there is a dose-related risk of vascular
disease). |
|
|
Adverse
Reactions |
|
>10%:
Cardiovascular: Peripheral edema
Endocrine & metabolic: Enlargement of breasts, breast tenderness
Gastrointestinal: Nausea, anorexia, bloating
1% to 10%:
Central nervous system: Headache
Endocrine & metabolic: Increased libido
Gastrointestinal: Vomiting, diarrhea
<1%: Hypertension, thromboembolism, stroke, myocardial infarction, edema,
depression, dizziness, anxiety, chloasma, melasma, rash, decreased glucose
tolerance, amenorrhea, alterations in frequency and flow of menses, increased
triglycerides and LDL, GI distress, cholestatic jaundice, intolerance to contact
lenses, increased susceptibility to Candida infection, breast tumors
Hormonal Balance in Oral Contraceptives:
Estrogen Excess: Nausea, bloating, cervical mucorrhea, polyposis,
melasma, migraine headache, breast fullness or tenderness, edema, hypertension
Estrogen Deficiency: Early or midcycle breakthrough bleeding,
increased spotting, hypomenorrhea
Progestin Excess: Increased appetite, weight gain, tiredness,
fatigue, hypomenorrhea, acne, oily scalp*, hair loss, hirsutism*, depression,
monilial vaginitis, breast regression
Progestin Deficiency: Late breakthrough bleeding, amenorrhea,
hypermenorrhea
*Result of androgenic activity of progestins
Pharmacological effects of progestins used in oral
contraceptives:
Norgestrel/levonorgestrel:
Progestin: Pronounced effect
Estrogen: No effect
Antiestrogen: Moderate effect
Androgen: Pronounced effect
Ethynodiol diacetate:
Progestin: Moderate effect
Estrogen: Slight effect*
Antiestrogen: Slight effect*
Androgen: Slight effect
Norethindrone acetate:
Progestin: Slight effect
Estrogen: Slight effect
Antiestrogen: Pronounced effect
Androgen: Slight effect
Norethindrone:
Progestin: Slight effect
Estrogen: Slight effect*
Antiestrogen +*
Androgen: Slight effect
Norethynodrel:
Progestin: Slight effect
Estrogen: Pronounced effect
Antiestrogen: No effect
Androgen: No effect
*Has estrogenic effect at low doses; may have antiestrogenic effect at higher
doses. |
|
|
Overdosage/Toxicology |
|
Toxicity is unlikely following single exposures of excessive doses
Any treatment following emesis and charcoal administration should be
supportive and symptomatic |
|
|
Drug
Interactions |
|
Ethinyl estradiol is a CYP3A3/4 and 3A5-7 enzyme substrate; CYP1A2 enzyme
inhibitor
Increased toxicity of acetaminophen, anticoagulants, benzodiazepines,
caffeine, corticosteroids, metoprolol, theophylline, tricyclic antidepressants
|
|
|
Mechanism of
Action |
|
Combination oral contraceptives inhibit ovulation via a negative feedback
mechanism on the hypothalamus, which alters the normal pattern of gonadotropin
secretion of a follicle-stimulating hormone (FSH) and luteinizing hormone by the
anterior pituitary. The follicular phase FSH and midcycle surge of gonadotropins
are inhibited. In addition, oral contraceptives produce alterations in the
genital tract, including changes in the cervical mucus, rendering it unfavorable
for sperm penetration even if ovulation occurs. Changes in the endometrium may
also occur, producing an unfavorable environment for nidation. Oral
contraceptive drugs may alter the tubal transport of the ova through the
fallopian tubes. Progestational agents may also alter sperm
fertility. |
|
|
Pharmacodynamics/Kinetics |
|
Ethinyl estradiol:
Absorption: Absorbed well from GI tract
Protein binding: 98%
Metabolism: Inactivated by liver
Half-life: 6-20 hours
Elimination: Bile and urine, enterohepatic recycling
Levonorgestrel:
Metabolism: Does not undergo first-pass effect; chiefly metabolized by
reduction and conjugation
Bioavailability: Completely
Half-life, terminal: 11-45 hours
Time to peak: 0.5-2 hours |
|
|
Usual Dosage |
|
Oral: Adults: Female: Contraception:
For 21-tablet package: Dosage is 1 tablet daily for 21 consecutive days,
followed by 7 days off of the medication; a new course begins on the 8th day
after the last tablet is taken.
For 28-tablet package: Dosage is 1 tablet daily without interruption.
Schedule 2 (Day 1 starter): Dose starts on first day of menstrual cycle
taking 1 tablet daily.
For 21-tablet package: Dosage is 1 tablet daily for 21 consecutive days,
followed by 7 days off of the medication; a new course begins on the 8th day
after the last tablet is taken.
For 28-tablet package: Dosage is 1 tablet daily without interruption.
If all doses have been taken on schedule and one menstrual period is missed,
continue dosing cycle. If two consecutive menstrual periods are missed,
pregnancy test is required before new dosing cycle is started.
Missed doses monophasic formulations (refer to package insert for
complete information):
One dose missed: Take as soon as remembered or take 2 tablets next day
Two consecutive doses missed in the first 2 weeks: Take 2 tablets as soon as
remembered or 2 tablets next 2 days. An additional method of contraception
should be used for 7 days after missed dose.
Two consecutive doses missed in week 3 or three consecutive doses missed at
any time: An additional method of contraception must be used for 7 days
after a missed dose.
Schedule 1 (Sunday starter): Continue dose of 1 tablet daily until Sunday,
then discard the rest of the pack, and a new pack should be started that same
day.
Schedule 2 (Day 1 starter): Current pack should be discarded, and a new pack
should be started that same day.
Missed doses biphasic/triphasic formulations (refer to package insert
for complete information):
One dose missed: Take as soon as remembered or take 2 tablets next day.
Two consecutive doses missed in week 1 or week 2 of the pack: Take 2 tablets
as soon as remembered and 2 tablets the next day. Resume taking 1 tablet daily
until the pack is empty. An additional method of contraception should be
used for 7 days after a missed dose.
Two consecutive doses missed in week 3 of the pack; An additional method
of contraception must be used for 7 days after a missed dose.
Schedule 1 (Sunday Starter): Take 1 tablet every day until Sunday. Discard
the remaining pack and start a new pack of pills on the same day.
Schedule 2 (Day 1 starter): Discard the remaining pack and start a new pack
the same day.
Three or more consecutive doses missed; An additional method of
contraception must be used for 7 days after a missed dose.
Schedule 1 (Sunday Starter): Take 1 tablet every day until Sunday; on Sunday,
discard the pack and start a new pack.
Schedule 2 (Day 1 Starter): Discard the remaining pack and begin new pack of
tablets starting on the same day. |
|
|
Dietary
Considerations |
|
Should be administered with food at same time each day |
|
|
Test
Interactions |
|
Decreased antithrombin III
Decreased serum folate concentration
Increased prothrombin and factors VII, VIII, IX, X
Increased platelet aggregability
Increased thyroid binding globulin
Increased total thyroid hormone (T4)
Increased serum triglycerides/phospholipids |
|
|
Dental Health: Local
Anesthetic/Vasoconstrictor
Precautions |
|
No information available to require special precautions |
|
|
Dental Health:
Effects on Dental Treatment |
|
When prescribing antibiotics, patient must be warned to use additional
methods of birth control if taking oral contraceptives |
|
|
Patient
Information |
|
Inform your physician if signs or symptoms of any of the following occur:
Thromboembolic or thrombotic disorders including sudden severe headache or
vomiting, disturbance of vision or speech, loss of vision, numbness or weakness
in an extremity, sharp or crushing chest pain, calf pain, shortness of breath,
severe abdominal pain or mass, mental depression or unusual bleeding
If any doses are missed, alternative contraceptive methods should be used for
the next 2 days or until 2 days into the new cycle
Discontinue taking the medication if you suspect you are pregnant or become
pregnant |
|
|
Nursing
Implications |
|
Inform your physician if signs or symptoms of any of the following occur:
Thromboembolic or thrombotic disorders including sudden severe headache or
vomiting, disturbance of vision or speech, loss of vision, numbness or weakness
in an extremity, sharp or crushing chest pain, calf pain, shortness of breath,
severe abdominal pain or mass, mental depression or unusual bleeding. If any
doses are missed, alternative contraceptive methods should be used for the next
2 days or until 2 days into the new cycle. Discontinue taking the medication if
you suspect you are pregnant or become pregnant. |
|
|
Dosage Forms |
|
Tablet:
Levlen®, Levora®,
Nordette®: Ethinyl estradiol 0.03 mg and levonorgestrel
0.15 mg (21s, 28s)
Tri-Levlen®, Triphasil®: Phase 1
(6 brown tablets): Ethinyl estradiol 0.03 mg and levonorgestrel 0.05 mg; Phase 2
(5 white tablets): Ethinyl estradiol 0.04 mg and levonorgestrel 0.075 mg; Phase
3 (10 yellow tablets): Ethinyl estradiol 0.03 mg and levonorgestrel 0.125 mg
(21s, 28s)
PREVEN™: Ethinyl estradiol 0.05 mg and levonorgestrel
0.25 mg (4 pills per kit along with a pregnancy test)
|
|
Copyright © 1978-2000 Lexi-Comp Inc. All Rights Reserved
| |